Evotec A.I CyberSecurity Scoring
07/04/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Evotec in 2026.
No incidents recorded for Evotec in 2026.
No incidents recorded for Evotec in 2026.
About Genentech We're passionate about finding solutions for people facing the world's most difficult-to-treat conditions. That is why we use cutting-edge science to create and deliver innovative medicines around the globe. To us, science is personal. Making a difference in the lives of millions starts when you make a change in yours. If you’d like to join our team, view our openings at gene.com/careers. Our patient resource center is dedicated to getting patients and caregivers to the right resources. You can reach them at 1 (877) GENENTECH (436-3683) Monday-Friday, 6am-5pm PST or [email protected]. Community Guidelines: 1. We want to foster positive conversation around the issues we are passionate about. To that end, we remove profanity, content that contains threatening language, content that is aimed at private individuals, personal information, and repeated unwanted messages. 2. Don’t mention any medicines by name — ours or anyone else’s. Because of the fair balance rules governing our industry, we cannot post any comments that reference any pharmaceutical brand, product, or service. Please do not mention any specific medicines by name, or include any links to third party sites in your comments. 3. This isn’t the place to report or discuss side effects. This site is not intended as a forum for reporting side effects experienced while taking a Genentech product. Instead, you should report any side effects to Genentech Drug Safety at 1-888-835-2555. You can also report side effects of any prescription product directly to the FDA at 1-800-FDA-1088 or by visiting www.FDA.gov/medwatch. 4. Don’t pitch your product or service. Please don't use our page as a place to promote your product or pitch your services. Please also avoid posting links to external sites. We reserve the right to remove any posts that are deemed promotional.
Avantor® is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development and production activities in the industries we serve. Our global footprint enables us to serve more than 300,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 14,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively. Visit our website to learn more about Avantor.
About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.
At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we're delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives. Social Media Guidelines: https://www.gilead.com/social-media-guidelines
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
Since 1987, Eurofins has grown from one laboratory in Nantes, France to over 65,000 staff across a network of independent companies in 60 countries, operating over 950 laboratories. Performing over 450 million tests every year, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as providing innovative clinical diagnostic testing services, as one of the leading global emerging players in specialised clinical diagnostics testing. Ever since its IPO on the French stock exchange in 1997, Eurofins has been one of the fastest growing listed European companies.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. We bring together a talented team of professionals with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.
Latest updates, reports, and threat intel affecting the global network.
Sandoz to acquire Just-Evotec Biologics' French facility for $300M, gaining automated continuous manufacturing capabilities.
Merck has settled with insurance companies that contested the pharma giant's $1.4B claim after it was victimized by a crippling cyberattack...
Evotec has recovered from a cyberattack it suffered this spring and is raising awareness of strategies other companies can take — alone and...
Werner Lanthaler rushed to the office the Friday before Easter after learning his biotech company Evotec had been hacked.
A New Jersey appellate court ruled that a group of insurers can't use war as an argument to deny Merck coverage from the notorious NotPetya...
German drug development giant Evotec is still recovering from a cyberattack that forced it to take all of its IT systems offline.
German biotech Evotec is on high alert after a late-week cyberattack prompted the company to shut down its network.
Vim is an open source, command line text editor. Prior to 9.2.0735, the C omni-completion script in runtime/autoload/ccomplete.vim interpolates the typeref: or typename: extension field of a tags entry, without escaping, into a :vimgrep pattern that is run through :execute. Because :vimgrep honors the bar as a command separator, a crafted tag field can close the search pattern and append an arbitrary Ex command; opening a hostile .c file whose project tags file contains such an entry and invoking C omni-completion runs that command as the editing user. This issue is fixed in version 9.2.0735.
Vim is an open source, command line text editor. Prior to 9.2.0725, the single-byte branch of spell_soundfold_sal() in src/spell.c translates a word through a spell file's SAL sound-folding rules into a caller-owned result buffer, but its result writes are guarded with reslen < MAXWLEN, allowing reslen to reach MAXWLEN before res[reslen] = NUL writes one byte past the end of the MAXWLEN-element stack buffer. A boundary-length word passed to soundfold(), or reached via sound-based spell suggestion while a SAL-based spell language is active under a non-multibyte 8-bit encoding, can corrupt the eval_soundfold() stack frame and crash the editor. This issue is fixed in version 9.2.0725.
Vim is an open source, command line text editor. Prior to 9.2.0736, the PHP omni-completion script in runtime/autoload/phpcomplete.vim interpolates a class or trait name, taken from the contents of the edited buffer, into a search() pattern that is run via win_execute() without escaping. A name containing a single quote can terminate the search() string argument early, and because the bar is honored as an Ex command separator, the remainder of the name is run as Ex commands; via the :! command this allows arbitrary operating-system command execution when a victim opens a crafted PHP file and invokes omni-completion. This issue is fixed in version 9.2.0736.
SiYuan is an open-source personal knowledge management system. Prior to 3.7.1, Asset.render in app/src/asset/index.ts interpolates the unsanitized this.path value into HTML assigned to innerHTML, allowing a crafted asset link containing a double quote to break out of the src attribute, inject an event handler, and execute JavaScript that can run OS commands in the Electron renderer. This issue is fixed in versions 3.7.1-alpha.2 and 3.7.1.
SiYuan is an open-source personal knowledge management system. Prior to 3.7.1, POST /api/file/globalCopyFiles accepts attacker-supplied absolute source paths and relies on util.IsSensitivePath in kernel/util/path.go, whose denylist misses common home-directory credential files such as .git-credentials, .netrc, .pgpass, .kube/config, .docker/config.json, and .gnupg, allowing an authenticated administrator or API-token user to copy those files into the workspace and exfiltrate them through the file API. This issue is fixed in versions 3.7.1-alpha.2 and 3.7.1.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.